Back
Repligen Corp. 10K Form
Buy
59
RGEN
Repligen Corp.
Last Price:
$165.83
Seasonality Move:
15.29%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-01 | 10Q | RGEN/Repligen Corp. Quarterly |
| 2023-10-31 | 10Q | RGEN/Repligen Corp. Quarterly |
| 2023-08-02 | 10Q | RGEN/Repligen Corp. Quarterly |
| 2023-05-02 | 10Q | RGEN/Repligen Corp. Quarterly |
| 2022-11-01 | 10Q | RGEN/Repligen Corp. Quarterly |
| 2022-08-02 | 10Q | RGEN/Repligen Corp. Quarterly |
Receive RGEN News And Ratings
See the #1 stock for the next 7 days that we like better than RGEN
RGEN Financial Statistics
Sales & Book Value
| Annual Sales: | $634.4M |
|---|---|
| Cash Flow: | $42.7M |
| Price / Cash Flow: | 90.79 |
| Annual Sales: | $37.01 |
| Price / Book: | 4.5 |
Profitability
| EPS (TTM): | 0.02580 |
|---|---|
| Net Income (TTM): | $1.7M |
| Gross Margin: | $284M |
| Return on Equity: | 0.09% |
| Return on Assets: | 0.06% |
Repligen Corp. Earnings Forecast
Key Repligen Corp. Financial Ratios
-
The Gross Profit Margin over the past 40 years for RGEN is 44.76%.
-
The Selling, General & Administrative Expenses for RGEN have been equal to 41.51% of Gross Profit Margin.
-
The Research & Development expenses have been 6.74% of Revenue.
-
The Net Earning history of RGEN is -4.02% of Total Revenues.
-
Per Share Earnings over the last 40 years have been positive in 19 years.
Repligen Corp. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Life Sciences Tools & Services |
| Sector: | Health Care |
| Current Symbol: | RGEN |
| CUSIP: | 759916 |
| Website: | repligen.com |
Debt
| Debt-to-Equity Ratio: | 0.33 |
|---|---|
| Current Ratio: | 8.36 |
| Quick Ratio: | 6.86 |
Price-to-Earnings
| Trailing P/E Ratio: | 258.21 |
|---|---|
| Forward P/E Ratio: | 79.63 |
RGEN Technical Analysis vs Fundamental Analysis
Buy
59
Repligen Corp. (RGEN)
is a Buy
Is Repligen Corp. a Buy or a Sell?
-
Repligen Corp. stock is rated a BuyThe current Repligen Corp. [RGEN] share price is $166.52. The Score for RGEN is 59, which is 18% above its historic median score of 50, and infers lower risk than normal.